Under a tenth of patients that would benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it releases its first guidance on the drugs.
Given more than one billion individuals worldwide now obese, it is urging increased and just access to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidelines acknowledges that obesity is a lifelong illness that can be managed with thorough and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are major obstacles to broad access to the jabs that can aid individuals in losing significant weight, explains the body.
Weight-Loss Drug Supply Crisis
Even under the present best projected case, the production of these medications might only reach approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The guideline encourages nations and manufacturers to widen availability, via strategies including voluntary licensing.
The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Drugs Function
These medications imitate a natural hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people reduce food intake.
Individuals usually begin shedding pounds after several weeks of starting on the regular doses.
Research points to people may put most of the weight back on a year later of discontinuing the medication, when their typical food cravings resume.
To be carrying excess weight raises your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
